Recent advances for FLAP inhibitors.

Abstract

A number of FLAP inhibitors have been progressed to clinical trials for respiratory and other inflammatory indications but so far no drug has reached the market. With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease. We also show how recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP inhibitors paving the way for new compound classes.

• Authors: Daniel Pettersen, Öjvind Davidsson, Carl Whatling
• Journal: Bioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 25 Issue 13 Pg. 2607-12 (Jul 01 2015) ISSN: 1464-3405 [Electronic] England
• PMID: 26004579 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• 5-Lipoxygenase-Activating Protein Inhibitors
• Leukotrienes

Topics

• 5-Lipoxygenase-Activating Protein Inhibitors (chemistry, pharmacology)
• Animals
• Asthma (drug therapy)
• Atherosclerosis (drug therapy)
• Drug Design
• Drug Discovery
• Humans
• Inflammation (drug therapy)
• Leukotrienes (metabolism)
• Molecular Structure